Woburn, MA-based Courtagen Life Sciences, has pinned down an $8 million equity investment from 67 backers, an SEC filing shows. The company raised $7 million in Series A funding in August 2010, under its previous name Avantra Biosciences. Courtagen is developing protein biomarker technology for disease detection. The technology was purchased from the now-bankrupt Decision Biomarkers by Courtagen Capital (the parent company of Courtagen Life Sciences) in 2009.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
